Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victoria Castel

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2011
miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samplesKatleen De Preter, Pieter Mestdagh, Joëlle Vermeulen, et al.
The Lancet. Oncology|March 6, 2017
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Andrew D J Pearson, et al.
The Lancet. Oncology|June 12, 2009
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH studyJoëlle Vermeulen, Katleen De Preter, Arlene Naranjo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2020
Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN StudyKeith Holmes, Ulrike Pötschger, Andrew D J Pearson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2021
Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)Angela Bellini, Ulrike Pötschger, Virginie Bernard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2020
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable <i>MYCN</i>-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation GroupInge M Ambros, Gian-Paolo Tonini, Ulrike Pötschger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma TrialLucas Moreno, Rebekah Weston, Cormac Owens, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2011
miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samplesKatleen De Preter, Pieter Mestdagh, Joëlle Vermeulen, et al.
The Lancet. Oncology|March 6, 2017
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Andrew D J Pearson, et al.
The Lancet. Oncology|June 12, 2009
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH studyJoëlle Vermeulen, Katleen De Preter, Arlene Naranjo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2020
Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN StudyKeith Holmes, Ulrike Pötschger, Andrew D J Pearson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2021
Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)Angela Bellini, Ulrike Pötschger, Virginie Bernard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2020
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable <i>MYCN</i>-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation GroupInge M Ambros, Gian-Paolo Tonini, Ulrike Pötschger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma TrialLucas Moreno, Rebekah Weston, Cormac Owens, et al.
Pageof 8